1. Product Overview: Daclaxen® is a direct-acting antiviral formulation containing Daclatasvir, used in combination therapy for the treatment of chronic Hepatitis C virus infection.

2. Composition: Daclatasvir INN 60 mg | Dosage Form: Tablet

3. Pharmacological Class: NS5A Inhibitor (Direct-Acting Antiviral)

4. Mechanism of Action: Daclatasvir inhibits the HCV NS5A protein, which is essential for viral RNA replication and assembly, thereby preventing the multiplication of the hepatitis C virus.

5. Indications: Chronic Hepatitis C virus (HCV) infection | Combination therapy for multiple HCV genotypes

6. Dosage & Administration: As directed by physician or hepatology specialist only | Oral use | Usually taken once daily | Used in combination with other antiviral agents

7. Clinical Benefits: Reduces HCV viral load | Helps achieve sustained virologic response (SVR) | Improves liver function | Reduces risk of liver complications

8. Contraindications: Hypersensitivity to Daclatasvir or any component of the formulation

9. Precautions: Must be used in combination therapy only | Liver function monitoring required | Risk of viral resistance if used improperly

10. Drug Interactions: May interact with strong CYP3A inducers or inhibitors such as rifampin, carbamazepine, and certain antifungals

11. Special Populations: Use in pregnancy and lactation only if clearly needed and prescribed | Pediatric use under specialist supervision

12. Adverse Effects: Headache | Fatigue | Nausea | Diarrhea | Mild elevation of liver enzymes

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Tablet blister pack

15. Manufacturer: Everest Pharmaceutical Ltd.